Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer

Published Date: 02 May 2026

Approval was based on findings from the phase 3 VERITAC-2 trial showing significantly improved PFS for patients with ESR1-mutated disease.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Immunotherapy Remains Little Used in Head and Neck Cancer

2.

Making informed decisions and managing regret after prostate cancer treatment

3.

Nodal Response After Chemo Helps Tailor Breast Radiotherapy

4.

Where Does Mistletoe Extract Fit in Supportive Cancer Care?

5.

The risk of lung cancer recurrence is linked to hypoxemia brought on by sleep apnea.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot